title: Impact of 1, 25-(OH)2D3 on Left Ventricular Hypertrophy in Type 2 Diabetic Rats.
abstract: OBJECTIVE
  To investigate the impact of 1, 25-(OH)2D3 on left ventricular hypertrophy (LVH) in type 2 diabetic rats.
  
  
  METHODS
  Type 2 diabetic mellitus (DM) model rats were established by intraperitoneally injecting with 30 mg/kg streptozotocin. After 8 weeks, 19 male rats were identified as diabetic with left ventricular hypertrophy (LVH) by ultrasound examination, and randomly assigned into three groups: untreated (DM-LVH, n=7), treated with insulin (DM-LVH+INS, n=6), and treated with 1, 25-(OH)2D3 (DM-LVH+VD, n=6). Healthy male rats were used as the controls group (n=6). The fasting blood glucose and the insulin level were determined weekly. The left ventricular mass index, myocardial collagen content, collagen volume fraction, and 1, 25-(OH)2D3-receptor level were determined by 4 weeks later.
  
  
  RESULTS
  In the DM-LVH model group, the insulin level was significantly decreased compared with the non-diabetic control group (P<0.05), whereas the blood glucose, left ventricular mass index, myocardial collagen content, collagen volume fraction, and 1, 25-(OH)2D3-receptor expression were significantly increased (all P<0.05). In the DM-LVH+INS and DM-LVH+VD groups, the insulin levels were significantly increased compared with the DM-LVH model group (P<0.05), whereas the other parameters were significantly decreased (all P<0.05).
  
  
  CONCLUSIONS
  1, 25-(OH)2D3 could reverse LVH in diabetic rats and that the mechanism may involve stimulating insulin secretion and reducing blood glucose via direct up-regulation of 1, 25-(OH)2D3-receptor expression.
authors.forename: Ying
authors.initials: Y
authors.lastname: Fan
authors.forename: Shan-xiao
authors.initials: SX
authors.lastname: Zhang
authors.forename: Meng
authors.initials: M
authors.lastname: Ren
authors.forename: Li-feng
authors.initials: LF
authors.lastname: Hong
authors.forename: Xiao-ni
authors.initials: XN
authors.lastname: Yan
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002117:Calcitriol / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D017379:Hypertrophy, Left Ventricular / Q000517:prevention & control*; D007328:Insulin / Q000097:blood; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D018167:Receptors, Calcitriol / Q000032:analysis; D013311:Streptozocin
chemical_list: D001786:Blood Glucose; D007328:Insulin; D018167:Receptors, Calcitriol; D013311:Streptozocin; D002117:Calcitriol